This week, Miami announced to be one of the three sites where health officials are bound to start the second phase of Zika vaccine testing. Specialists are testing an experimental vaccine to combat the terrible virus. The DNA vaccine was created by scientists at the National Institute of Allergy and Infectious Diseases, being part of the National Institute of Health.
The new Zika vaccine will be tested in sites like Puerto Rico, Miami and Mexico
The clinical trial is prone to enroll about 2,490 healthy participants in regions where Zika was confirmed, or there was a potential active spread. The list includes Mexico, Panama, Costa Rica, Peru, Brazil, Puerto Rico, Houston, and Miami. The clinical trial in South Florida will develop at the University of Miami Miller School of Medicine. Margaret Fischl is an UM infectious disease physician and scientist who is responsible for conducting daily reviews regarding the safety information. There, the trial will start next week.
The second phase of the clinical trial is called VRC 705 and is bound to investigate three important things. Firstly, it will analyze the safety of this Zika vaccine for humans. Secondly, it will look at its ability to trigger an efficient immune response. Scientists will also take care of establishing the optimal dose for treatment. The clinical trial is bound to determine whether this vaccine will prevent Zika virus transmission.
The vaccine candidate starting being tested last year
The vaccine candidate had begun being tested on humans in 2016 after it was first tested on animals. NIH reported that initial results suggested that the vaccine was safe and it induced a neutralizing antibody outcome against Zika virus. In the first part of the trial, about 90 non-pregnant women and healthy men will be enrolled, with ages between 18 and 35 in Puerto Rico, San Juan, Miami, Houston.
All participants who were recruited for the trial will get vaccinated with the vaccine candidate in three distinct visits which were scheduled to be four weeks apart. They will be randomly assigned to get a high dose or a standard one during those three visits. The second phase of the trial will recruit about 2,400 non-pregnant women and healthy men with ages between 15 and 35 establishing whether the new Zika vaccine can protect them against the virus. The regions include Mexico, Panama, Brazil, Peru, Costa Rica, San Juan, Miami, Houston.
Image source: flickr